126 related articles for article (PubMed ID: 22811898)
1. Neopterin as a marker of response to antiviral therapy in hepatitis C virus patients.
Oxenkrug GF; Requintina PJ; Mikolich DL; Ruthazer R; Viveiros K; Lee H; Summergrad P
Hepat Res Treat; 2012; 2012():619609. PubMed ID: 22811898
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
3. Atorvastatin in Combination with Pegylated Interferon and Ribavirin Provided High Rate of Sustained Virological Response in Patients with Genotype 3 Hepatitis C Virus.
Todorovska B; Caloska-Ivanova V; Dimitrova-Genadieva M; Trajkovska M; Popova-Jovanovska R; Grivceva-Stardelova K; Licoska-Josifovic F; Andreevski V; Curakova-Ristovska E; Joksimovic N
Open Access Maced J Med Sci; 2019 May; 7(10):1641-1648. PubMed ID: 31210815
[TBL] [Abstract][Full Text] [Related]
4. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
5. Rapid virological response assessment by Abbott RealTime hepatitis C virus assay for predicting sustained virological responses in patients with hepatitis C virus genotype 1 treated with pegylated-interferon and ribavirin.
Su PY; Yen HH; Hsu YC; Wu SS; Kor CT; Su WW
Kaohsiung J Med Sci; 2016 Jul; 32(7):381-6. PubMed ID: 27450028
[TBL] [Abstract][Full Text] [Related]
6. New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.
Abe H; Aida Y; Ishiguro H; Yoshizawa K; Seki N; Miyazaki T; Itagaki M; Sutoh S; Ika M; Kato K; Shimada N; Tsubota A; Aizawa Y
J Med Virol; 2013 Sep; 85(9):1523-33. PubMed ID: 23775277
[TBL] [Abstract][Full Text] [Related]
7. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence.
Bizollon T; Ahmed SN; Radenne S; Chevallier M; Chevallier P; Parvaz P; Guichard S; Ducerf C; Baulieux J; Zoulim F; Trepo C
Gut; 2003 Feb; 52(2):283-7. PubMed ID: 12524414
[TBL] [Abstract][Full Text] [Related]
8. Sustained virological response rates to antiviral therapy in genotype 1 and 3 chronic hepatitis C patients: a study from north India.
Gupta V; Kumar A; Sharma P; Tyagi P; Bansal N; Singla V; Arora A
J Clin Exp Hepatol; 2014 Dec; 4(4):287-92. PubMed ID: 25755575
[TBL] [Abstract][Full Text] [Related]
9. Daily interferon induction regimen using different manufactured interferons (alpha-2A or alpha-2B) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study.
Braga EL; Lyra AC; Nascimento L; Netto E; Kalabrik L; Lyra LG
Arq Gastroenterol; 2006; 43(4):275-9. PubMed ID: 17406754
[TBL] [Abstract][Full Text] [Related]
10. Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin.
Perrella A; Sbreglia C; Atripaldi L; Esposito C; D'Antonio A; Perrella O
Scand J Gastroenterol; 2010; 45(2):250-5. PubMed ID: 19968615
[TBL] [Abstract][Full Text] [Related]
11. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
[TBL] [Abstract][Full Text] [Related]
12. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
13. Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b.
Yoshizawa K; Abe H; Aida Y; Ishiguro H; Ika M; Shimada N; Tsubota A; Aizawa Y
J Med Virol; 2013 Jul; 85(7):1180-90. PubMed ID: 23918536
[TBL] [Abstract][Full Text] [Related]
14. Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C.
Bizollon T; Adham M; Pradat P; Chevallier M; Ducerf C; Baulieux J; Zoulim F; Trepo C
Transplantation; 2005 Feb; 79(3):325-9. PubMed ID: 15699763
[TBL] [Abstract][Full Text] [Related]
15. IP-10 Serum Level in Chronic Hepatitis C Virus Patients: Relation to Fibrosis and Response to Combined Interferon/Ribavirin Therapy.
El Raziky M; Elsharkawy A; Said SE; Abdelatty S; El Akel W; Tantawy O; Gamal Eldeen H; Mabrouk M
J Interferon Cytokine Res; 2015 Aug; 35(8):649-53. PubMed ID: 25973761
[TBL] [Abstract][Full Text] [Related]
16. [Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
Pár A; Tornai I; Szalay F
Orv Hetil; 2007 May; 148(18):819-26. PubMed ID: 17468063
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory markers neopterin and alanine aminotransferase in HCV patients treated with HCV NS3.4A protease inhibitor telaprevir (VX-950) and/or peginterferon alfa-2a.
Gelderblom HC; Zeuzem S; Weegink CJ; Forestier N; Mcnair L; Purdy S; Dijkgraaf MG; Jansen PL; Reesink HW
Scand J Gastroenterol; 2008; 43(9):1122-7. PubMed ID: 18609142
[TBL] [Abstract][Full Text] [Related]
18. Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing.
Neff GW; O'Brien CB; Cirocco R; Montalbano M; de Medina M; Ruiz P; Khaled AS; Bejarano PA; Safdar K; Hill MA; Tzakis AG; Schiff ER
Liver Transpl; 2004 May; 10(5):595-8. PubMed ID: 15108250
[TBL] [Abstract][Full Text] [Related]
19. Serum concentrations of sIL-2R, IL-6, TGF-beta1, neopterin, and zinc in chronic hepatitis C patients treated with interferon-alpha.
Grüngreiff K; Reinhold D; Ansorge S
Cytokine; 1999 Dec; 11(12):1076-80. PubMed ID: 10623433
[TBL] [Abstract][Full Text] [Related]
20. The accuracy and cost-effectiveness of hepatitis C core antigen assay in the monitoring of anti-viral therapy in patients with chronic hepatitis C genotype 4.
Kamal SM; Kassim S; El Gohary E; Fouad A; Nabegh L; Hafez T; Bahnasy K; Hassan H; Ghoraba D
Aliment Pharmacol Ther; 2015 Aug; 42(3):307-18. PubMed ID: 26018116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
